Share Article
FOSTER CITY, Calif.--(BUSINESS WIRE)--July 11, 2003--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the registration statement relating to the Company's 2% Convertible Subordinated Notes and the common stock into which the notes are convertible (collectively, the "Securities") was declared effective by the Securities and Exchange Commission on July 9, 2003.
Selling Securityholders included in the registration statement may obtain a copy of the prospectus relating to the Securities by contacting Joshua D. Gillespie via email at jgillespie@cooley.com or by phone at 650/843-5000.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has seven marketed products and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.
For more information on Gilead Sciences, please visit the company's web site at www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
CONTACT: Gilead Sciences, Inc. Susan Hubbard, 650/522-5715 (Investor Relations)
SOURCE: Gilead Sciences
Other News
Some of the content on this page is not intended for users outside the U.S.